In the text below the calculator there is more information about the index variables and its interpretation.
The triglyceride and glucose index was originally proposed as a marker of insulin resistance (study by Guerrero-Romero et al.).
In 2017, Zhang et al. compared the predictive value of ALT (alanine aminotransferase laboratory determination) to that of TyG in identifying patients at risk for non-alcoholic fatty liver disease.
The following table summarizes the two cut-off points identified, for insulin resistance and NAFLD positive diagnosis likelihood:
|Condition||Cut-off value||Values below cut-off||Values above cut-off|
|Insulin resistance||4.49||Insulin resistance unlikely||Suggestive of insulin resistance|
|Nonalcoholic fatty liver disease||8.5||NAFLD diagnosis is unlikely||High likelihood of NAFLD|
Send Us Your Feedback
Steps on how to print your input & results:
1. Fill in the calculator/tool with your values and/or your answer choices and press Calculate.
2. Then you can click on the Print button to open a PDF in a separate window with the inputs and results. You can further save the PDF or print it.
Please note that once you have closed the PDF you need to click on the Calculate button before you try opening it again, otherwise the input and/or results may not appear in the pdf.
TyG index explained
The triglyceride and glucose index is a screening method for insulin resistance that is very simple to use and only requires two laboratory determinations: serum triglycerides and serum glucose.
According to a study by Salazar et al. insulin resistance cut off is placed at the TyG index value of 4.49, with a sensitivity of 82.6% and specificity of 82.1% (AUC=0.889, 95% CI: 0.854-0.924)
Subjects with an index of 4.49 or greater are likely to suffer from insulin resistance.
The TyG equation is:
TyG = ln [Fasting triglyceride (mg / dl) x Fasting glucose (mg / dl)] / 2
Ultrasound is the first-line tool to detect liver steatosis but it may not be fully available or may require extra costs. It also has the limitation of detecting steatosis if present in more than 20-30% of hepatocytes. Therefore, prediction tools that are less costly and non-invasive are being sought.
The TyG is considered a screening tool for large-scale studies. The reason is its accuracy and easiness to be calculated with data obtained from medical records.
In the comparative study by Fedchuk et al. on the performance and limitations of steatosis biormarkers in patients with NAFLD, TyG is one of the example tools for steatosis, with an AUROC of 0.90. The gold standard for steatosis diagnosis is in this case liver biopsy.
According to Fedchuk et al. at TyG values above 8.38, there was a positive predictive value (PPV) of 99% for predicting steatosis equal to or greater than 5%.
A recent cross sectional study by Zhang et al. aimed to determine whether TyG has any predictive value for NAFLD. To do that it compared the predictive value of TyG with that of determinations of ALT (alanine aminotransferase) in a cohort of 10,761 patients where non-alcoholic fatty liver disease was diagnosed via ultrasonography.
The association between a screening method using triglycerides and glucose should not come as a surprise as NAFLD is considered the liver manifestation of metabolic syndrome, while triglyceride and serum glucose are key components of this process.
Alanine aminotransferase is the liver enzyme most reflective of liver fat content and is often included as variable with high prediction value in hepatic steatosis biomarkers.
ALT is also considered as a non-traditional cardiometabolic risk factor, meaning that it can be associated with type 2 diabetes, metabolic syndrome and risk of cardiovascular disease.
The study has found that the prevalence of NAFLD was significantly increased along the increasing levels of TyG and ALT but that TyG performed better than ALT in discriminating NAFLD.
According to the ROC analysis, the optimal cut-off point of TyG for NAFLD was 8.5. The AUROC was 0.782 (95% CI 0.773–0.790). TyG of 8.5 and above identified cases with NAFLD with 72.2% sensitivity and 70.5% specificity.
Hepatic steatosis predictors
There are several other screening tools for non-alcoholic fatty liver disease, including:
1. Salazar J et al. Optimal cutoff for the evaluation of insulin resistance through triglyceride-glucose index: A cross-sectional study in a Venezuelan population. Version 3. F1000Res. 2017; 6: 1337.
2. Zhang S, Du T et al. The triglyceride and glucose index (TyG) is an effective biomarker to identify nonalcoholic fatty liver disease. Lipids Health Dis. 2017; 16: 15.
1. Simental-Mendía LE, Rodríguez-Morán M, Guerrero-Romero F. The product of fasting glucose and triglycerides as surrogate for identifying insulin resistance in apparently healthy subjects. Metab Syndr Relat Disord. 2008; 6(4):299-304.
2. Fedchuk L, Nascimbeni F, Pais R, Charlotte F, Housset C, Ratziu V; LIDO Study Group. Performance and limitations of steatosis biomarkers in patients with nonalcoholic fatty liver disease. Aliment Pharmacol Ther. 2014; 40(10):1209-22.
3. Guerrero-Romero F, Simental-Mendia LE, Gonzalez-Ortiz M, et al. The product of triglycerides and glucose, a simple measure of insulin sensitivity. Comparison with the euglycemichyperinsulinemic clamp. J Clin Endocrinol Metab 2010; 95: 3347–51.
Article reviewed by Dr. Antonio Olveira
App Version: 1.0.1
Coded By: MDApp
No. Of Variables: 2
Year Of Study: 2008
Published On: September 11, 2017 · 09:29 AM
Last Checked: September 11, 2017
Next Review: September 11, 2018